Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 301–400 of 1,001
Stricker, S. H., Feber, A., Engström, P. G., Carén, H., Kurian, K. M., Takashima, Y., Watts, C., Way, M., Dirks, P. B., Bertone, P., et al. (2013) · Genes & Development · doi:10.1101/gad.212662.112 · Cited by 148
“In vitro expansion of NS cells and GBMderived stem cells as primary cell lines is possible by propagating them as neurospheres in suspension culture (Singh et al. 2003; Galli et al. 2004; Lee et al. 2006) or in adherent culture conditions (Pollard et al. 2009).”
BackgroundPlacing the HIRA Histone Chaperone Complex in the Chromatin Landscape
Pchelintsev, N. A., McBryan, T., Rai, T. S., van Tuyn, J., Ray-Gallet, D., Almouzni, G., & Adams, P. D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.026 · Cited by 143
“3 is mutated in human cancer (Schwartzentruber et al., 2012; Wu et al., 2012).”
Cohen, K. J., Jabado, N., & Grill, J. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox021 · Cited by 162
Self-citationDiverse involvement of EZH2 in cancer epigenetics.
Völkel, P., Dupret, B., Bourhis, X. L., & Angrand, P. (2015) · PubMed · Cited by 174
Break induced replication in eukaryotes: mechanisms, functions, and consequences
Sakofsky, C. J., & Malkova, A. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1314444 · Cited by 128
“3 that are enriched in ALT positive tumors (Heaphy et al., 2011; Schwartzentruber et al., 2012).”
Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase
Yang, S., Zheng, X., Lü, C., Li, G., Allis, C. D., & Li, H. (2016) · Genes & Development · doi:10.1101/gad.284323.116 · Cited by 149
“For example, the H3K27Mmutation was identified in the majority of pediatric diffuse intrinsic pontine gliomas (Schwartzentruber et al. 2012; Wu et al. 2012), and the H3K36M mutation was found to occur predominantly in chondroblastomas (Behjati et al.”
BackgroundInfluentialHistone Regulation in the CNS: Basic Principles of Epigenetic Plasticity
Maze, I. S., Noh, K., & Allis, C. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.124 · Cited by 154
Cancer and Telomeres—An ALTernative to Telomerase
Shay, J. W., Reddel, R. R., & Wright, W. E. (2012) · Science · doi:10.1126/science.1222394 · Cited by 153
Histone H3.3 Mutations: A Variant Path to Cancer
Yuen, B. T. K., & Knoepfler, P. S. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.015 · Cited by 134
“K27M tumors (both low- and high-grade) are primarily restricted to midline locations (spinal cord, thalamus, pons, brainstem) and G34R/V tumors to cerebral hemispheres (Figure 1A; Bjerke et al., 2013; Sturm et al., 2012).”
BackgroundInfluentialBéchet, D., Gielen, G. H., Korshunov, A., Pfister, S. M., Rousso, C., Faury, D., Fiset, P., Benlimame, N., Lewis, P. W., Lü, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1337-4 · Cited by 144
Self-citationCastel, D., Philippe, C., Kergrohen, T., Sill, M., Merlevede, J., Barret, E., Puget, S., Sainte‐Rose, C., Kramm, C. M., Jones, C., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0614-1 · Cited by 146
Self-citationSievers, P., Sill, M., Schrimpf, D., Stichel, D., Reuß, D., Sturm, D., Hench, J., Frank, S., Krsková, L., Vícha, A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa251 · Cited by 139
Self-citationPrecision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 145
Jamieson, K., Wiles, E. T., McNaught, K. J., Sidoli, S., Leggett, N., Shao, Y., Garcia, B. A., & Selker, E. U. (2016) · Genome Research · doi:10.1101/gr.194555.115 · Cited by 128
“…is critical for normal development in flies, plants, and other systems (Schwartz and Pirrotta 2007), and recent work implicates perturbation of H3K27me in a high fraction of pediatric gliomas (Schwartzentruber et al. 2012; Sturm et al. 2012; Wu et al. 2012; Chan et al. 2013; Lewis et al. 2013).”
BackgroundHistone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding
Lv, D., Feng, J., Hou, Y., Sang, Y., Alvarez, A. A., Zhang, W., Gao, W., Hu, B., Cheng, S., Ge, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1388 · Cited by 140
“Recent global genomic and transcriptome analyses reveal that the epigenetic landscape is deregulated in cancer, including glioma, partially due to aberrant histone modifications and mutations (2-4).”
BackgroundChudnovsky, Y., Kim, D., Zheng, S., Whyte, W. A., Bansal, M., Bray, M.-A., Gopal, S., Theisen, M. A., Bilodeau, S., Thiru, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.032 · Cited by 136
“Recent work implicates alterations in epigenetic regulation as a key step during gliomagenesis (Lewis et al., 2013; Schwartzentruber et al., 2012; Wu et al., 2012).”
BackgroundLin, C.-J., Conti, M., & Ramalho-Santos, M. (2013) · Development · doi:10.1242/dev.095513 · Cited by 130
“3, including at G34, have recently been reported in pediatric glioblastoma (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012), and it may prove fruitful to explore whether these mutations affect K36 methylation or the ability to antagonize H1.”
BackgroundH3F3A K27M Mutation in Pediatric CNS Tumors
Gielen, G. H., Gessi, M., Hammes, J., Kramm, C. M., Waha, A., & Pietsch, T. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpabohbc33fvmo · Cited by 145
Self-citationAmary, F. M., Berisha, F., Mozela, R., Gibbons, R., Guttridge, A., O’Donnell, P., Baumhoer, D., Tirabosco, R., & Flanagan, A. M. (2016) · Histopathology · doi:10.1111/his.12945 · Cited by 142
“H3F3 alterations have also been reported in paediatric brain tumours, specifically in up to 60% of diffuse intrinsic pontine gliomas.(6,9) However, as these do not enter the differential diagnosis of bone and soft tissue tumours, we have excluded them from this study.”
BackgroundIs histone acetylation the most important physiological function for CBP and p300?
Bedford, D. C., & Brindle, P. K. (2012) · Aging · doi:10.18632/aging.100453 · Cited by 154
Li, F., Deng, Z., Zhang, L., Wu, C., Jin, Y., Hwang, I., Vladimirova, O. V., Xu, L., Yang, L., Lu, B., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201796659 · Cited by 142
“…commonly DAXX ) loss-of-function mutations were identified in a variety of cancer types including pediatric and adult gliomas (Jiao et al , 2012; Schwartzentruber et al , 2012; Brennan et al , 2013; Zhang et al , 2013; Wu et al , 2014; Brat et al , 2015), pancreatic neuroendocrine tumor (Jiao…”
Oncogenic extracellular vesicles in brain tumor progression
D’Asti, E., Garnier, D., Lee, T. H., Montermini, L., Meehan, B., & Rak, J. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00294 · Cited by 129
Insights into molecular therapy of glioma: current challenges and next generation blueprint
Rajesh, Y., Pal, I., Banik, P., Chakraborty, S., Borkar, S. A., Dey, G., Mukherjee, A., & Mandal, M. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.167 · Cited by 138
Nussinov, R., Jang, H., Tsai, C.-J., & Cheng, F. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 130
Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials
Vitanza, N. A., & Monje, M. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0577-y · Cited by 144
Emerging roles for Polycomb proteins in cancer
Pasini, D., & Di Croce, L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.013 · Cited by 133
“1 in paediatric diffuse intrinsic pontine gliomas (DIPGs) arising from the brainstem [86,87], is also directly linked to PRC2 lossof-function.”
Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3–MutSα interaction
Fang, J., Huang, Y., Mao, G., Yang, S., Rennert, G., Gu, L., Li, H., & Li, G.-M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806355115 · Cited by 125
“The data are from cancer genome studies deposited in the ICGC database (15, 16).”
BackgroundMethodACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis
Hoeman, C. M., Cordero, F. J., Hu, G., Misuraca, K., Romero, M. M., Cardona, H. J., Nazarian, J., Hashizume, R., McLendon, R. E., Yu, P. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08823-9 · Cited by 140
Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Lowe, B. R., Maxham, L., Hamey, J. J., Wilkins, M. R., & Partridge, J. F. (2019) · Cancers · doi:10.3390/cancers11050660 · Cited by 144
“Mutations in TP53 and PDGFRA (platelet derived growth factor alpha) are often found to be associated with H3.”
BackgroundInfluentialAtrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span
Watson, L. A., Solomon, L. A., Li, J. R., Jiang, Y., Edwards, M., Shin-ya, K., Beier, F., & Bérubé, N. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65634 · Cited by 130
“Mutations in the ATRX gene were identified in several types of cancers, including pediatric brain tumors (5–7, 9, 10).”
The chromatin remodeller ATRX: a repeat offender in human disease
Clynes, D., Higgs, D. R., & Gibbons, R. J. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.06.011 · Cited by 147
Cancer epigenetics: Past, present and future
Lee, J. E., & Kim, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.025 · Cited by 148
Systems biology: personalized medicine for the future?
Chen, R., & Snyder, M. P. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.011 · Cited by 152
“Sequenced cancer genomes include breast cancer [6–8], ovarian cancer [9], small-cell lung cancer [10], melanoma [11], chronic lymphocytic leukemia [12], Sonic-Hedgehog medulloblastoma [13], pediatric glioblastoma [14], and hepatocellular carcinoma [15], just to name a few.”
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
Gonzalez-Perez, A., Jene-Sanz, A., & Lopez-Bigas, N. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 125
“BRAIN PEDIATRIC DKFZ Pediatric brain tumors DKFZ ICGC DCC 113 [90,91]”
SMARCAL1 Resolves Replication Stress at ALT Telomeres
Cox, K. E., Maréchal, A., & Flynn, R. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.011 · Cited by 141
Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Johung, T., & Monje, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160509123229 · Cited by 144
“1, the alteration is a specific missense mutation resulting in the substitution of lysine with methionine at position 27 (K27M) [49, 50].”
InfluentialYamamoto, H., Iwasaki, T., Yamada, Y., Matsumoto, Y., Otsuka, H., Yoshimoto, M., Kohashi, K., Taguchi, K., Yokoyama, R., Nakashima, Y., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.11.020 · Cited by 136
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
Bellizzi, A. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000256 · Cited by 139
Diffuse intrinsic pontine glioma: a reassessment
Robison, N. J., & Kieran, M. W. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1448-8 · Cited by 135
Shaping the cellular landscape with Set2/SETD2 methylation
McDaniel, S. L., & Strahl, B. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2517-x · Cited by 136
NuRD–ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination
Conomos, D., Reddel, R. R., & Pickett, H. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2877 · Cited by 129
Silveira, A. B., Kasper, L. H., Fan, Y., Jin, H., Wu, G., Shaw, T. I., Zhu, X., Larson, J. D., Easton, J. B., Shao, Y., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01975-4 · Cited by 134
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma
Buczkowicz, P., & Hawkins, C. E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00147 · Cited by 139
“Mutations of chromatin remodeling genes are less common in DIPG than in supratentorial HGA (3, 24).”
BackgroundInfluentialNew Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 147
Experimental models and tools to tackle glioblastoma
Robertson, F., Marqués‐Torrejón, M. Á., Morrison, G. M., & Pollard, S. M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040386 · Cited by 132
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model
Haag, D., Mack, N. L., da Silva, P. B. G., Statz, B., Clark, J., Tanabe, K., Sharma, T., Jäger, N., Jones, D., Kawauchi, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.005 · Cited by 137
Self-citationATRX immunostaining predicts IDH and H3F3A status in gliomas
Ebrahimi, A., Skardelly, M., Bonzheim, I., Ott, I., Mühleisen, H., Eckert, F., Tabatabai, G., & Schittenhelm, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0331-6 · Cited by 134
“Missense and truncating mutations of ATRX gene lead to loss of expression in gliomas [8, 9] and correlates with better clinical outcome in a subset of IDH1 mutant tumors [11].”
BackgroundA new genomic framework to categorize pediatric acute myeloid leukemia
Umeda, M., Ma, J., Westover, T., Ni, Y., Song, G., Maciaszek, J. L., Rusch, M., Rahbarinia, D., Foy, S. G., Huang, B. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01640-3 · Cited by 136
“Some cases without category-defining alterations could be characterized by rare fusion or mutations, which need further evidence to establish as a disease entity, including MLLT1 and H3F3A mutations that are frequent and class-defining in Wilms tumor 57 and glioma 58 , respectively.”
BackgroundEgan, C. M., Nyman, U., Skotte, J., Streubel, G., Turner, S. A., O’Connell, D. J., Rraklli, V., Dolan, M.-J., Chadderton, N., Hansen, K. H., et al. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.07.008 · Cited by 136
“EZH2 has also been reported to be deleted and have inactivating mutations in certain myeloid leukemias (Ernst et al., 2010; Nikoloski et al., 2010), and the histone H3 residue H3K27 is itself mutated in juvenile glioblastomas (Schwartzentruber et al., 2012).”
BackgroundPediatric Brain Tumor Genetics: What Radiologists Need to Know
AlRayahi, J., Zápotocký, M., Ramaswamy, V., Hanagandi, P. B., Branson, H. M., Mubarak, W. M., Raybaud, C., & Laughlin, S. (2018) · Radiographics · doi:10.1148/rg.2018180109 · Cited by 131
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Mueller, S., Taitt, J. M., Villanueva-Meyer, J. E., Bonner, E. R., Nejo, T., Lulla, R. R., Goldman, S., Banerjee, A., Chi, S. N., Whipple, N. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140378 · Cited by 121
TERT Promoter Alterations in Glioblastoma: A Systematic Review
Olympios, N., Gilard, V., Marguet, F., Clatot, F., Fiore, F. D., & Fontanilles, M. (2021) · Cancers · doi:10.3390/cancers13051147 · Cited by 137
“In 2012, the first genome-wide sequencing among pediatric high-grade gliomas study identified a high frequency of alterations associated with histone modifications [85].”
BackgroundMolecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 137
Self-citationKurmasheva, R. T., Sammons, M. C., Favours, E., Wu, J., Kurmashev, D., Cosmopoulos, K., Keilhack, H., Klaus, C. R., Houghton, P. J., & Smith, M. A. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26218 · Cited by 129
A complex Polycomb issue: the two faces of EZH2 in cancer
Hock, H. (2012) · Genes & Development · doi:10.1101/gad.191163.112 · Cited by 121
“Moreover, very recently, this residue was found to be subject to very distinct, recurrent mutations in three types of aggressive pediatric brain tumors (Schwartzentruber et al. 2012; Wu et al. 2012).”
BackgroundCanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
Mao, Y., Chen, H., Liang, H., Meric-Bernstam, F., Mills, G. B., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077945 · Cited by 122
“Research that interrogate specific driver mutations and their clinical implications are being widely conducted for multiple types of cancer [7,8], however, more”
BackgroundKhan, S. A., Reddy, D., & Gupta, S. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.333 · Cited by 130
Appin, C., & Brat, D. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000020 · Cited by 136
“Those GBMs mutated at K27 occurred in young children (median age, 11 years) and were midline in location (pons and thalamus), whereas those mutated at G34 occurred in teenagers and young adults and were located in the cerebral hemispheres.(44) H3F3A mutations were found to be highly specific to GBMs, more frequent in…”
BackgroundInfluentialEpidemiology, diagnosis, and optimal management of glioma in adolescents and young adults
Diwanji, T. P., Engelman, A., Snider, J. W., III, & Mohindra, P. (2017) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s53391 · Cited by 146
“3, at positions K27 and G34, have more recently been focused upon for their oncogenic tendencies and prognostic value.(55) The K27, RTK-I, and PXA-like subtypes are characteristically encountered more often in the AYA and pediatric populations.”
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 130
“3, DAXX mutation is relatively rare compared to H3F3A and ATRX (69).”
BackgroundAguilera, P., & Lopez-Contreras, A. J. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.02.009 · Cited by 124
Carén, H., Stricker, S. H., Bulstrode, H. J. C. J., Gagrica, S., Johnstone, E. R., Bartlett, T. E., Feber, A., Wilson, G. A., Teschendorff, A. E., Bertone, P., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.09.014 · Cited by 128
“It will be important to explore whether differentiation therapy might have value for other forms of glioma, particularly those that are driven by mutations in core epigenetic regulators, such as pediatric high-grade glioma (Wu et al., 2012; Schwartzentruber et al., 2012), ependymoma (Mack et al.”
Feng, J., Hao, S., Pan, C., Wang, Y., Wu, Z., Zhang, J., Yan, H., Zhang, L., & Wan, H. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.07.002 · Cited by 123
McDonald-McGinn, D. M., Fahiminiya, S., Revil, T., Nowakowska, B. A., Suhl, J., Bailey, A., Mlynarski, E., Lynch, D. R., Yan, A. C., Bilaniuk, L. T., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101320 · Cited by 116
Filipescu, D., Müller, S., & Almouzni, G. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013311 · Cited by 116
Nikiforova, M. N., Wald, A. I., Melan, M. A., Roy, S., Zhong, S., Hamilton, R. L., Lieberman, F. S., Drappatz, J., Amankulor, N., Pollack, I. F., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov289 · Cited by 127
“Pediatric gliomas are unique and feature mutations in H3F3A, ATRX, and BRAF, but IDH mutations are rare unless the patient is an adolescent.(7,8) Circumscribed lower-grade gliomas such as pilocytic astrocytoma, pilomyxoid astrocytoma, ganglioglioma, and pleomorphic xanthoastrocytoma often harbor mutations or gene fusi…”
BackgroundNon-invasive metabolic imaging of brain tumours in the era of precision medicine
Kim, M. M., Parolia, A., Dunphy, M. P., & Venneti, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.108 · Cited by 117
Structure of the variant histone H3.3–H4 heterodimer in complex with its chaperone DAXX
Liu, C.-P., Xiong, C., Wang, M., Yu, Z., Yang, N., Chen, P., Zhang, Z., Li, G., & Xu, R.-M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2439 · Cited by 120
Saratsis, A. M., Kambhampati, M., Snyder, K. A., Yadavilli, S., Devaney, J. M., Harmon, B. T., Hall, J., Raabe, E. H., An, P., Weingart, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1218-2 · Cited by 135
“recent studies also associated MYC and MYCN amplification with DIPg, [24, 27, 28, 57] which are consistent with our finding of increased MYCN expression in four of five H3F3A mutants (Online resource 10).”
Ryall, S. T., Krishnatry, R., Arnoldo, A., Buczkowicz, P., Mistry, M., Siddaway, R., Ling, C., Pajovic, S., Yu, M., Rubin, J. B., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0353-0 · Cited by 121
“This result coincides with our previous work in DIPG [5, 20], where we found H3K27M to be a negative prognostic marker in DIPG, albeit independent of tumour histology.”
BackgroundResultInfluentialSelf-citationK27M-mutant histone-3 as a novel target for glioma immunotherapy
Ochs, K., Ott, M., Bunse, T., Sahm, F., Bunse, L., Deumelandt, K., Sonner, J. K., Keil, M., von Deimling, A., Wick, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328340 · Cited by 122
“An amino acid exchange from lysine to methionine at position 27 (K27M) leads to the reduction of H3K27 trimethylation resulting in a distinct global methylation and gene expression pattern.(5,6,7,8) Besides, gliomas harboring H3K27M lack hallmark cytogenetic aberrations usually found in high-grade gliomas and are char…”
BackgroundATRX Dysfunction Induces Replication Defects in Primary Mouse Cells
Clynes, D., Jelinska, C., Xella, B., Ayyub, H., Taylor, S., Mitson, M., Bachrati, C. Z., Higgs, D. R., & Gibbons, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092915 · Cited by 115
“Interestingly, a role for ATRX in facilitating replication through potential G-quadruplex forming sequences may shed light on its recently ascribed role as a tumor suppressor in a specific subset of malignancies that depend on a telomerase-independent pathway of telomere maintenance called the ‘alternative lengthening…”
BackgroundEpigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 129
Cohen, A. R. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2116344 · Cited by 130
Role of the Microenvironment in Glioma Pathogenesis
Jayaram, M. A., & Phillips, J. J. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-110348 · Cited by 129
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications
Wang, W. T., Qin, J., Voruganti, S., Nag, S. A., Zhou, J., & Zhang, R. (2015) · Medicinal Research Reviews · doi:10.1002/med.21358 · Cited by 126
Abedalthagafi, M., Phillips, J. J., Kim, G., Mueller, S., Haas-Kogen, D. A., Marshall, R. E., Croul, S. E., Santi, M., Cheng, J. Q., Zhou, S., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.90 · Cited by 127
Serresi, M., Gargiulo, G., Proost, N., Siteur, B., Cesaroni, M., Koppens, M. A. J., Xie, H., Sutherland, K. D., Hulsman, D., Citterio, E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.006 · Cited by 128
“In particular, the recent efforts in cancer genome sequencing revealed genetic mutations implicating key components of PRC2 as context-dependent tumor suppressors (De Raedt et al., 2014; Schwartzentruber et al., 2012; Zhang et al., 2014).”
BackgroundSchulte, J. D., Buerki, R. A., Lapointe, S., Molinaro, A. M., Zhang, Y., Villanueva-Meyer, J. E., Perry, A., Phillips, J. J., Tihan, T., Bollen, A. W., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa142 · Cited by 129
Rauch, F., Moffatt, P., Cheung, M., Roughley, P. J., Lalic, L., Lund, A. M., Ramírez, N., Fahiminiya, S., Majewski, J., & Glorieux, F. H. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101307 · Cited by 116
Self-citationAltered Histone Modifications in Gliomas
Kim, Y. Z. (2014) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2014.2.1.7 · Cited by 130
“Screening of a large cohort of gliomas of various grades and histologies (n=784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults [74].”
BackgroundAlternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Hartlieb, S., Sieverling, L., Nadler-Holly, M., Ziehm, M., Toprak, U. H., Herrmann, C., Ishaque, N., Okonechnikov, K., Gartlgruber, M., Park, Y.-G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21247-8 · Cited by 124
“CC + stage 1-3 (4) CC + stage 4 (14) CC + 19”
Self-citationAksenova, A. Y., & Mirkin, S. M. (2019) · Genes · doi:10.3390/genes10020118 · Cited by 117
Establishment of age group classification for risk stratification in glioma patients
Lin, Z., Yang, R., Li, K., Yi, G., Li, Z., Guo, J., Zhang, Z., Junxiang, P., Liu, Y., Qi, S., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01888-w · Cited by 124
Prediction of histone post-translational modification patterns based on nascent transcription data
Wang, Z., Chivu, A. G., Choate, L. A., Rice, E. J., Miller, D. C., Chu, T., Chou, S.-P., Kingsley, N. B., Petersen, J. L., Finno, C. J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01026-x · Cited by 105
Broniscer, A., Tatevossian, R., Sabin, N. D., Klimo, P. D., Dalton, J., Lee, R. P., Gajjar, A. J., & Ellison, D. W. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12093 · Cited by 114
PML body meets telomere: The beginning of an ALTernate ending?
Chung, I., Osterwald, S., Deeg, K. I., & Rippe, K. (2012) · Nucleus · doi:10.4161/nucl.20326 · Cited by 135
A Developmental Requirement for HIRA-Dependent H3.3 Deposition Revealed at Gastrulation in Xenopus
Szenker, E., Lacoste, N., & Almouzni, G. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.006 · Cited by 102
“Most recently, in human, the observations of somatic mutations affecting H3 variants or their chaperones in specific pediatric tumors further emphasize the importance of considering their role in a developmental context (Schwartzentruber et al., 2012; Wu et al., 2012).”
BackgroundARHGDIA : a novel gene implicated in nephrotic syndrome
Gupta, I. R., Baldwin, C., Auguste, D., Ha, K., Andalousi, J. E., Fahiminiya, S., Bitzan, M. M., Bernard, C., Akbari, M. R., Narod, S. A., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101442 · Cited by 112
Self-citationATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress
Teng, Y., Sundaresan, A., O’Hara, R. A., Gant, V. U., Li, M., Martire, S., Warshaw, J. N., Basu, A. B., & Banaszynski, L. A. (2021) · Nature Communications · doi:10.1038/s41467-021-24206-5 · Cited by 119
Brown, Z. Z., Müller, M. M., Jain, S. U., Allis, C. D., Lewis, P. W., & Muir, T. W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5060934 · Cited by 111
An Update on Neurofibromatosis Type 1-Associated Gliomas
Lobbous, M., Bernstock, J. D., Coffee, E., Friedman, G. K., Metrock, L. K., Chagoya, G., Elsayed, G., Nakano, I., Hackney, J. R., Korf, B. R., et al. (2020) · Cancers · doi:10.3390/cancers12010114 · Cited by 113
“3 histone genes, frequently found in sporadic pediatric gliomas [32], were absent in all samples regardless of age.”
BackgroundEpigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 117
“There has been a surge in interest in the function of H3K27 methylation in glioma following landmark studies identifying mutations in histone H3 at a high-frequency in pediatric glioma, implicating mutant histones as potential oncogenes in cancer for the first time (Schwartzentruber et al., 2012; Wu et al., 2012).”
BackgroundInfluentialExomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas
Joseph, C. G., Hwang, H., Jiao, Y., Wood, L. D., Kinde, I., Wu, J., Mandahl, N., Luo, J., Hruban, R. H., Diaz, L. A., et al. (2014) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22114 · Cited by 109
Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment
Zhou, Z., Singh, R., & Souweidane, M. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160614093615 · Cited by 120
“3, is identified in 10-14% of pediatric supratentorial GBMs [64, 66] but not in any of the 90 DIPG samples analyzed by two groups [64, 65].”
Bressan, R. B., Dewari, P. S., Kalantzaki, M., Gangoso, E., Matjusaitis, M., Garcia-Diaz, C., Blin, C., Grant, V., Bulstrode, H. J. C. J., Gogolok, S., et al. (2017) · Development · doi:10.1242/dev.140855 · Cited by 113
“3 and result in single amino acid substitutions (either K27M or G34R/V) (Schwartzentruber et al., 2012; Wu et al., 2012).”
BackgroundExtensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres
Dagg, R. A., Pickett, H. A., Neumann, A. A., Napier, C. E., Henson, J. D., Teber, E. T., Arthur, J. W., Reynolds, C. P., Murray, J., Haber, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.087 · Cited by 110
Bailey, S., Howman, A. J., Wheatley, K., Wherton, D., Boota, N., Pizer, B. L., Fisher, D., Kearns, P. R., Picton, S. V., Saran, F. H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.006 · Cited by 112
Massimino, M., Biassoni, V., Miceli, R., Schiavello, E., Warmuth‐Metz, M., Modena, P., Casanova, M., Pecori, E., Giangaspero, F., Antonelli, M., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1428-z · Cited by 113
“Based on previously-published scientific grounds [8–15], as mentioned earlier, a phase II study by Bode et al.”
BackgroundResultH3K36me3, message from chromatin to DNA damage repair
Sun, Z., Zhang, Y., Jia, J., Fang, Y., Tang, Y., Wu, H., & Fang, D. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-0374-z · Cited by 109
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.